Innocare Pharma Shares Surge Over 5% on Positive Phase III Data for Tafasitamab Combo in Frontline DLBCL

Stock News06-18

Shares of Innocare Pharma Limited (ASX: 09969) rose more than 5% during the trading session. At the time of writing, the stock was up 3.29% to HK$10.69, with a turnover of approximately HK$43.05 million.

The catalyst for the move was news released on June 18th. The company announced that the results from the global Phase III frontMIND study for its tafasitamab combination therapy were presented in an oral report at the plenary session of the 2026 European Hematology Association (EHA) Congress.

The findings demonstrated that, compared to the current first-line standard-of-care R-CHOP regimen, the combination of tafasitamab, lenalidomide, and R-CHOP (Tafa-Len-R-CHOP) showed a significant improvement in progression-free survival (PFS). The results were reported to be both statistically significant and of substantial clinical value.

This therapy holds the potential to offer a new first-line standard treatment option for patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100666683?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 11:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100666683","market":"hk","top_or_hot":-1,"title":"Innocare Pharma Shares Surge Over 5% on Positive Phase III Data for Tafasitamab Combo in Frontline DLBCL","media":"Stock News","content":"<p>Shares of <b>Innocare Pharma Limited</b> (<b>ASX</b>: <b>09969</b>) rose more than 5% during the trading session. At the time of writing, the stock was up 3.29% to HK$10.69, with a turnover of approximately HK$43.05 million.<br><br>\nThe catalyst for the move was news released on June 18th. The company announced that the results from the global Phase III frontMIND study for its tafasitamab combination therapy were presented in an oral report at the plenary session of the 2026 European Hematology Association (EHA) Congress.<br><br>\nThe findings demonstrated that, compared to the current first-line standard-of-care R-CHOP regimen, the combination of tafasitamab, lenalidomide, and R-CHOP (Tafa-Len-R-CHOP) showed a significant improvement in progression-free survival (PFS). The results were reported to be both statistically significant and of substantial clinical value.<br><br>\nThis therapy holds the potential to offer a new first-line standard treatment option for patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innocare Pharma Shares Surge Over 5% on Positive Phase III Data for Tafasitamab Combo in Frontline DLBCL</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnocare Pharma Shares Surge Over 5% on Positive Phase III Data for Tafasitamab Combo in Frontline DLBCL\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-18 11:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Innocare Pharma Limited</b> (<b>ASX</b>: <b>09969</b>) rose more than 5% during the trading session. At the time of writing, the stock was up 3.29% to HK$10.69, with a turnover of approximately HK$43.05 million.<br><br>\nThe catalyst for the move was news released on June 18th. The company announced that the results from the global Phase III frontMIND study for its tafasitamab combination therapy were presented in an oral report at the plenary session of the 2026 European Hematology Association (EHA) Congress.<br><br>\nThe findings demonstrated that, compared to the current first-line standard-of-care R-CHOP regimen, the combination of tafasitamab, lenalidomide, and R-CHOP (Tafa-Len-R-CHOP) showed a significant improvement in progression-free survival (PFS). The results were reported to be both statistically significant and of substantial clinical value.<br><br>\nThis therapy holds the potential to offer a new first-line standard treatment option for patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688428","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1100666683","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100666683","pubTimestamp":1781751628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of Innocare Pharma Limited (ASX: 09969) rose more than 5% during the trading session. At the time of writing, the stock was up 3.29% to HK$10.69, with a turnover of approximately HK$43.05...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","09969":"诺诚健华","BK0239":"医药制造","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK1161":"生物科技","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"诺诚健华医药股价因Tafasitamab组合治疗一线DLBCL的积极III期数据而飙升超过5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"VXUS":1,"09969":1},"content_text":"Shares of Innocare Pharma Limited (ASX: 09969) rose more than 5% during the trading session. At the time of writing, the stock was up 3.29% to HK$10.69, with a turnover of approximately HK$43.05 million.\nThe catalyst for the move was news released on June 18th. The company announced that the results from the global Phase III frontMIND study for its tafasitamab combination therapy were presented in an oral report at the plenary session of the 2026 European Hematology Association (EHA) Congress.\nThe findings demonstrated that, compared to the current first-line standard-of-care R-CHOP regimen, the combination of tafasitamab, lenalidomide, and R-CHOP (Tafa-Len-R-CHOP) showed a significant improvement in progression-free survival (PFS). The results were reported to be both statistically significant and of substantial clinical value.\nThis therapy holds the potential to offer a new first-line standard treatment option for patients with high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100666683","isCrawlerRequest":true}